NanoViricides (NNVC) Competitors $1.31 -0.02 (-1.20%) (As of 09:35 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrends NNVC vs. VTGN, BCAB, CTMX, BYSI, LPTX, ALVR, SPRO, ALXO, ALGS, and CELUShould you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Vistagen Therapeutics (VTGN), BioAtla (BCAB), CytomX Therapeutics (CTMX), BeyondSpring (BYSI), Leap Therapeutics (LPTX), AlloVir (ALVR), Spero Therapeutics (SPRO), ALX Oncology (ALXO), Aligos Therapeutics (ALGS), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry. NanoViricides vs. Vistagen Therapeutics BioAtla CytomX Therapeutics BeyondSpring Leap Therapeutics AlloVir Spero Therapeutics ALX Oncology Aligos Therapeutics Celularity Vistagen Therapeutics (NASDAQ:VTGN) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking. Is VTGN or NNVC more profitable? NanoViricides has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -4,521.71%. Vistagen Therapeutics' return on equity of -36.35% beat NanoViricides' return on equity.Company Net Margins Return on Equity Return on Assets Vistagen Therapeutics-4,521.71% -36.35% -33.62% NanoViricides N/A -84.63%-76.49% Do analysts prefer VTGN or NNVC? Vistagen Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 481.40%. Given Vistagen Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vistagen Therapeutics is more favorable than NanoViricides.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50NanoViricides 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, VTGN or NNVC? NanoViricides has lower revenue, but higher earnings than Vistagen Therapeutics. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistagen Therapeutics$1.06M67.76-$29.36M-$1.24-2.08NanoViricidesN/AN/A-$8.29M-$0.76-1.73 Does the media prefer VTGN or NNVC? In the previous week, Vistagen Therapeutics and Vistagen Therapeutics both had 1 articles in the media. Vistagen Therapeutics' average media sentiment score of 1.75 beat NanoViricides' score of 0.33 indicating that Vistagen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vistagen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in VTGN or NNVC? 78.4% of Vistagen Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 1.3% of Vistagen Therapeutics shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in VTGN or NNVC? Vistagen Therapeutics received 282 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 0.00% of users gave NanoViricides an outperform vote. CompanyUnderperformOutperformVistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% NanoViricidesOutperform VotesNo VotesUnderperform Votes57100.00% Which has more risk & volatility, VTGN or NNVC? Vistagen Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. SummaryVistagen Therapeutics beats NanoViricides on 11 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NNVC vs. The Competition Export to ExcelMetricNanoViricidesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$18.41M$6.45B$5.06B$19.88BDividend YieldN/A8.11%5.18%3.52%P/E Ratio-1.7410.78126.3142.94Price / SalesN/A243.711,178.7419.18Price / CashN/A22.1633.8617.86Price / Book1.365.474.685.52Net Income-$8.29M$153.61M$119.54M$986.45M7 Day Performance0.38%-2.00%-1.83%0.45%1 Month Performance-9.59%-7.46%-3.60%1.05%1 Year Performance21.10%31.82%31.91%24.67% NanoViricides Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NNVCNanoViricidesN/A$1.31-1.2%N/A+15.8%$18.33MN/A-1.7320Analyst DowngradeVTGNVistagen Therapeutics3.774 of 5 stars$2.58-1.1%$15.00+481.4%-25.4%$71.83M$1.06M0.0040Positive NewsBCABBioAtla2.8165 of 5 stars$1.46-1.4%$6.00+311.0%-11.4%$70.59M$250,000.000.0060Short Interest ↓CTMXCytomX Therapeutics4.3829 of 5 stars$0.87+0.3%$5.77+561.1%-37.4%$68.33M$101.21M5.12170Short Interest ↓BYSIBeyondSpringN/A$1.71-0.6%N/A+86.1%$66.74M$1.75M0.0080LPTXLeap Therapeutics2.3936 of 5 stars$2.59-4.1%$7.50+189.6%+25.1%$66.30M$1.50M0.0040Positive NewsALVRAlloVir2.6268 of 5 stars$0.570.0%N/A-65.2%$65.86MN/A0.00110Positive NewsSPROSpero Therapeutics4.5933 of 5 stars$1.20flat$5.00+316.7%-2.4%$65.42M$103.78M17.1546Analyst ForecastALXOALX Oncology3.3343 of 5 stars$1.23+1.7%$12.50+916.3%-87.7%$64.87MN/A0.0040ALGSAligos Therapeutics4.1561 of 5 stars$17.90-1.6%$75.00+319.0%+5.5%$64.26M$15.53M-1.3790CELUCelularity0.5369 of 5 stars$2.90-1.4%N/A+42.7%$63.77M$22.77M0.00220News Coverage Related Companies and Tools Related Companies Vistagen Therapeutics Alternatives BioAtla Alternatives CytomX Therapeutics Alternatives BeyondSpring Alternatives Leap Therapeutics Alternatives AlloVir Alternatives Spero Therapeutics Alternatives ALX Oncology Alternatives Aligos Therapeutics Alternatives Celularity Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NNVC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NNVC Stock Alerts